TP53 and acute myeloid leukemia: Furthermore, another multi-center, open label, phase II clinical trial to assess the safety and efficacy of APR-246 in combination with azacitidine as maintenance therapy after allogeneic HSCT for patients with TP53 mutant AML or MDS is also ongoing (NCT03931291) (Table 2).